ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at [email protected] Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
01/20/201716:01:00Merck Announces Settlement and License Agreement Resolving KEYTRUDA®...
01/20/201706:01:00Merck and Genea Open Centre of Excellence for Fertility
01/19/201701:30:00MSD for Mothers Commits $10 Million & Bus. Expertise to the Global...
01/18/201709:00:00Merck Foundation Grant Expands Project ECHO® in Vietnam and...
01/17/201716:47:01Statement of Changes in Beneficial Ownership (4)
01/12/201703:03:00Health Stocks Fall as Trump Slams Industry -- WSJ
01/10/201716:06:00Merck Receives FDA Acceptance of Supplemental Biologics License...
01/09/201708:00:00Incyte & Merck to Advance Clinical Development Program Investigating...
01/06/201708:00:00Merck to Participate at the 35th Annual J.P. Morgan Healthcare...
01/04/201715:05:00Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate--Update
01/04/201711:32:00Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate
01/03/201716:14:49Statement of Changes in Beneficial Ownership (4)
01/03/201716:14:24Statement of Changes in Beneficial Ownership (4)
01/03/201716:14:24Statement of Changes in Beneficial Ownership (4)
01/03/201716:14:24Statement of Changes in Beneficial Ownership (4)
01/03/201706:45:00Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings...
12/28/201603:02:00Ahead of the Tape: Trump Gives 'Dogs of the Dow' Pause -- WSJ
12/27/201616:28:00Donald Trump Dogs Dow Strategy -- Ahead of the Tape
12/19/201617:52:00Biogen Names New CEO -- Update
12/19/201607:00:00KEYTRUDA® (pembrolizumab) Approved as First Anti-PD-1 Therapy...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US